Prepare to Give Nirsevimab to Prevent RSV

You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.

We know that RSV is the most common cause of hospitalization in US infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.

Nirsevimab is a monoclonal antibody given IM in the clinic or hospital...similar to palivizumab (Synagis).